...
首页> 外文期刊>European journal of clinical nutrition >A non-hydrolyzed, fermented milk formula reduces digestive and respiratory events in infants at high risk of allergy.
【24h】

A non-hydrolyzed, fermented milk formula reduces digestive and respiratory events in infants at high risk of allergy.

机译:非水解发酵乳配方奶粉可降低高过敏风险婴儿的消化系统和呼吸系统事件。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND/OBJECTIVES: To determine the impact of a not hydrolyzed fermented infant formula containing heat-killed Bifidobacterium breve C50 and Streptococcus thermophilus 065 (HKBBST) on the incidence of allergy-like events during the first 2 years of life in children at high risk of atopy. SUBJECTS/METHODS: This multicenter, randomized, double-blind, controlled study included infants at high risk of atopy. Infants used HKBBST or a standard infant formula (SIF) since birth until 1 year of age, and were followed at 4, 12 and 24 months after birth. Skin prick tests (SPTs) for six foods and six aeroallergens were systematically performed and adverse events (AEs) were recorded. In case of potentially allergic AE (PAAE), allergy could be further tested by SPT, patch tests and quantification of specific IgEs. If cow's milk allergy (CMA) was suspected, an oral challenge could also be performed. RESULTS: The study included 129 children, 63 were randomized to SIF, 66 to HKBBST. The use of HKBBST milk did not alter the proportion of CMA but decreased the proportion of positive SPT to cow's milk (1.7 vs 12.5%, P=0.03), and the incidence of digestive (39 vs 63%, P=0.01) and respiratory potentially allergic AEs (7 vs 21%, P=0.03) at 12 months, and that of respiratory PAAEs at 24 months (13 vs 35%, P=0.01). CONCLUSIONS: HKBBST decreased the incidence of PAAEs in children with family history of atopy, during the first months of life and after the formula was stopped. Oral tolerance to cow's milk in infants at high risk of atopy may therefore be improved using not hydrolyzed fermented formulae.
机译:背景/目的:确定未水解发酵的婴儿配方奶粉,该奶粉含有热杀死的短双歧杆菌C50和嗜热链球菌065(HKBBST),对高危儿童中头两年的过敏样事件的发生率有影响特应性受试者/方法:这项多中心,随机,双盲,对照研究包括特应性高风险婴儿。婴儿自出生至1岁为止一直使用HKBBST或标准婴儿配方食品(SIF),并在出生后4、12和24个月随访。系统地对六种食物和六种空气过敏原进行了皮肤点刺试验(SPT),并记录了不良事件(AE)。如果是潜在的过敏性AE(PAAE),则可以通过SPT,斑贴试验和特定IgE的定量进一步检测过敏。如果怀疑牛奶过敏(CMA),也可以进行口服挑战。结果:该研究包括129名儿童,其中63名被随机分配到SIF,66名被随机分配到HKBBST。使用HKBBST牛奶不会改变CMA的比例,但会降低阳性SPT对牛奶的比例(1.7对12.5%,P = 0.03),消化率和呼吸道疾病的发生率(39对63%,P = 0.01)和呼吸道在12个月时有潜在过敏性AE(7比21%,P = 0.03),在24个月时有呼吸性PAAE(13比35%,P = 0.01)。结论:HKBBST降低了患有特应性家族史的儿童在出生后的头几个月以及停止该配方奶粉后PAAE的发生率。因此,使用未水解的发酵配方奶可以改善患有极应性疾病的婴儿对牛奶的口服耐受性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号